Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Ltd recently announced positive Phase II data from a clinical trial of its RECCE® 327 gel, demonstrating a 93% primary efficacy endpoint achieved over 14 days of treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including Diabetic Foot Infections. The study exceeded objectives, supporting an accelerated pathway for commercialization. With successful outcomes for both the DFI Indonesian Study and advancement to Registrational Phase 3 in Australia, the trial continues to showcase the efficacy of Recce’s synthetic technology. Notably, the company's innovative regulatory strategy is facilitating late-stage clinical trials with potential commercialization by 2026.

Investors are encouraged to review the detailed results and implications outlined in the recent announcement. The robust dataset, coupled with the potential market opportunities in the global ABSSSI treatment sector, positions Recce Pharmaceuticals favorably in addressing critical medical needs.

Recce Pharmaceuticals Ltd recently announced positive Phase II data from a clinical trial of its RECCE® 327 gel, demonstrating a 93% primary efficacy endpoint achieved over 14 days of treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including Diabetic Foot Infections. The study exceeded objectives, supporting an accelerated pathway for commercialization. With successful outcomes for both the DFI Indonesian Study and advancement to Registrational Phase 3 in Australia, the trial continues to showcase the efficacy of Recce’s synthetic technology. Notably, the company's innovative regulatory strategy is facilitating late-stage clinical trials with potential commercialization by 2026.<br/><br/>Investors are encouraged to review the detailed results and implications outlined in the recent announcement. The robust dataset, coupled with the potential market opportunities in the global ABSSSI treatment sector, positions Recce Pharmaceuticals favorably in addressing critical medical needs. Management remains confident in the broad-spectrum nature and rapid onset of R327G's effects, supported by positive expert evaluations. Questions regarding the announcement or the company's strategic direction are welcome as we move forward with our clinical programs and Phase 3 trials.

Positive Phase II Data from Clinical Trial of R327 Gel

Summary